Fighting Monopoly Power

Pharmacy

Local pharmacies are vanishing across the U.S, which is feeding the spread of pharmacy deserts in both urban and rural communities. These independent pharmacies are being muscled out while the pharmacy sector consolidates. Fortunately, there is much that a state government can do to level the playing field for independents.


by Zach Freed*

*Zach Freed is a researcher with ILSR who leads the Institute’s advocacy and outreach efforts.

Local pharmacies are vanishing across the U.S, feeding the spread of “pharmacy deserts,” or places that have no pharmacies within an easy distance. The disappearance of these crucial sources of healthcare is afflicting a growing number of both rural and urban communities. Since 2013, more than 400 pharmacies have closed in Ohio alone. A 2018 study from the University of Iowa found that over 600 rural communities that had at least one retail pharmacy (independent, chain, or franchise) in 2003 had none 15 years later. In America’s cities, Black and Latinx neighborhoods are much more likely to be pharmacy deserts, which is raising serious concerns about diminishing access to medicine and is further driving health disparities for people of color.[1]

Learn more about our Pharmacy Research
View Research →

Even as the Covid-19 crisis continues to illustrate the dangers of sparse provision of basic health care services, independent pharmacies are being muscled out while the pharmacy sector consolidates and important supply chains collapse. Fortunately, there is much that a state government can do to level the playing field for independents.

PBM Market Power and Self-Dealing

Why are local, independent pharmacies shuttering in rural and urban America? Many assume it is because they can’t compete with the larger chains, including CVS, Rite-Aid, and Walgreens, which, together with mail-order pharmacies, now capture 62 percent of prescription revenue.[2] In fact, research has found that independent pharmacies outperform the chains on several important measures. They provide more one-on-one consultation with patients, shorter wait times, and lower prices.[3] The real reason independents are disappearing is that corporations called Pharmacy Benefits Managers (PBMs) have been quietly running them out of business.[4]

Research has found that independent pharmacies outperform the chains on several important measures. They provide more one-on-one consultation with patients, shorter wait times, and lower prices.

PBMs are powerful corporations that oversee drug benefits for health plans. They determine, among other things, the drugs that insurers will cover and the reimbursement amount a pharmacy receives for filling a prescription. Only three companies make up 70 percent of the PBM market and all three operate their own mail-order pharmacies: OptumRx, owned by UnitedHealth Group; Express Scripts, owned by Cigna; and CVS Caremark, part of CVS Health, which recently acquired the health insurer Aetna. The largest PBM, CVS, also controls the largest pharmacy chain in the country. Between its stores and mail-order pharmacy, CVS alone captures almost one-quarter of prescription revenue.[4]

PBMs comprise one of the most poorly regulated sectors in the health care industry. This allows them, along with their sheer size and central position in the industry, to steer customers toward their own pharmacy services, a clear conflict of interest. They use several tactics to undermine competition, lock in their structural advantage over independent pharmacies, and monopolize the pharmacy market. Examples of these tactics include:

  • PBMs have a well-documented history of overcharging state health plans and cutting reimbursement rates to competing independent pharmacies, often below cost, which forces them out of business. In some cases, when pharmacies close, CVS’s “acquisitions unit” sends a letter to those same pharmacies offering to buy them.
  • Some PBMs impose mandatory mail-order clauses on health plans and their customers, steering patients to the PBM’s own mail-order services rather than from a local pharmacy.
  • PBMs themselves “regulate” pharmacies. In theory, this role helps eliminate unnecessary and fraudulent spending and helps ensure pharmacies are upholding high standards for recordkeeping and serving their customers. In practice, PBMs have a record of pushing community pharmacies out of their networks for small administrative errors. This tactic then allows PBMs to steer customers toward their own mail-order services, concentrating their hold on the pharmacy market that they themselves are supposed to be monitoring.[5]

Federal Policies: The Fox is Guarding the Henhouse

The power of PBMs is not an inevitable result of market competition. It is a result of specific federal policy choices. For years, federal antitrust enforcers have allowed the big three PBMs to consolidate power through mergers and self-dealing. Between 2007 and 2015, the Federal Trade Commission (FTC) approved a series of PBM mergers, including the CVS-Caremark merger, CVS-Omnicare, and Express Scripts-Medco. In 2018, the Department of Justice allowed CVS-Caremark to merge with Aetna, further consolidating CVS’s leverage over its competitors, particularly smaller pharmacies.

Beyond lax merger enforcement, federal regulators have discouraged state actors from intervening in the PBM industry. Between 2004 and 2011, the FTC sent a series of letters to state legislators deterring efforts to regulate the PBM industry. In these letters, the FTC argued that PBMs reduced drug costs, and that subjecting them to regulation and oversight would make it harder for them to do so, even as mounting evidence made it clear that PBMs engaged in self-dealing. In addition, the agency published two studies in the mid-aughts. The first FTC study found the PBM industry to be competitive, and the second discouraged any regulation that mandated transparency around PBM contracts with states. PBM industry lobbyists have repeatedly cited these FTC documents as proof that state oversight and regulation would raise drug prices.[6]

Despite the FTC’s discouragement, some states have begun to fight the market power of PBMs, often starting with PBM’s role managing prescription benefits for state health plans. States entered into contracts with PBMs based on the understanding that they would negotiate down prices with drug makers. However, PBMs have been caught overcharging Medicaid and other state insurance plans. Kentucky’s Cabinet for Health and Family Services, for example, found that PBMs overcharged the state $123.5 million in 2018. After conducting a similar review, Ohio Attorney General Dave Yost wrote that “when state agencies entered into these nebulous deals with PBMs, they unknowingly hired a fox to guard the henhouse. But he was a smart fox. He didn’t kill the chickens; he helped himself to the eggs.” Now some state attorneys general are fighting the foxes by suing PBMs for their blatant self-dealing.[7]

The Broader Impacts

PBM predatory practices often force pharmacies to close for good, which is devastating for patients and local communities for two reasons. First, research finds that independents deliver better prices on medicines than chains. Second, local, independent pharmacies are also an important component of quality healthcare. These pharmacists develop relationships with patients and understand the needs of their communities better than chain pharmacies, which are solely focused on the bottom line. According to a National Community Pharmacists Association, 71 percent of independent pharmacies provide in-person home delivery. In medically underserved areas, independent pharmacies also help patients adhere to life-saving medication regimes. Given these reasons, it is not surprising that patients tend to prefer independent pharmacies over chains.[8]

Taking Back State Power

While the problems we outline are byproducts of bad federal policy, there is much that states can do to tackle pharmacy concentration and pharmacy deserts. In fact, North Dakota’s pharmacy ownership law has proven a successful way to encourage local business ownership and keep drug costs low.[9] The list below provides some examples of how state actors can encourage local pharmacy ownership and mandate fair PBM conduct and transparency.

Enact Pharmacy Ownership Laws

States also have the authority to structure the pharmacy market. One shining example of a state policy that mandates local control is North Dakota’s law requiring that only licensed pharmacists can own pharmacies. Thanks to this law — which is unique among U.S. states, but similar to laws on the books in many other countries — today there are almost no chain pharmacies in North Dakota.[10]

Allow State Agencies to Oversee PBMs: PBM Licensure & Registration

These laws require PBMs to register with a state’s board of pharmacy or department of insurance authority and give these agencies the power to oversee PBMs. This gives pharmacies and insurance plan sponsors, including employers, recourse if a PBM is abusing its power. One of Washington State’s PBM laws requires that a PBM registers with the office of insurance commissioner, which has the power to resolve disputes with PBMs and issue fines. Under this type of law, if a PBM has demonstrably abused its power, the state authority can refuse to reissue the PBM license.

Require Transparency

Regulating PBM’s self-dealing requires adequate transparency of their pricing practices. PBM’s “spread pricing” tactic involves overcharging insurers while short-changing local pharmacies and pocketing the difference. PBMs get away with this, in part, by keeping their price lists secret.

  • Maximum Allowable Cost (MAC) transparency laws — on the books in 38 states — allow plan sponsors and pharmacists to see what the PBM is charging and allow them to receive prompt alerts when a PBM changes a price for a generic drug. See Kentucky’s example of MAC transparency laws.[11]
  • While MAC transparency laws are a good first step, they alone are insufficient to determine whether a PBM is engaging in self-dealing.[12] Good transparency laws require drug-level pricing information from all supply chain participants (manufacturer, insurer, and PBM). Nevada and Vermont both have laws like this.[13]

Restrict DIR Fees

To make up for lost profit in the wake of MAC transparency laws, PBMs have shifted their strategy, and started to misuse an opaque type of fee, called direct remuneration (DIR) fees, to arbitrarily “tax” pharmacies. Between 2010 and 2017, there was a 45,000 percent increase in these types of fees paid by pharmacies to PBMs. Connecticut recently passed legislation to restrict DIR fees.[14]

Enact “Any Willing Pharmacy” Laws

Managed care plans sometimes exclude certain health care providers, including independent pharmacies, from their list of accepted providers, even when they meet the plan’s terms and conditions. “Any Willing Pharmacy” laws prohibit this practice, allowing patients to choose from any provider that meets the state’s requirements. A handful of states, including New Hampshire, New Jersey, and Maine, have passed different types of “Any Willing Pharmacy” laws.[15]

Change the Rules for Medicaid: Ban Spread Pricing or Eliminate PBMs Altogether 

One approach that does not require legislation is to take action through state Medicaid agencies. Ohio’s state Medicaid agency recently ordered its managed care health plans to end their contracts with PBMs and renegotiate new contracts that will only pay PBMs a set fee for service. This prevents spread pricing. In 2018, West Virginia’s state Medicaid agency stopped using PBMs altogether for its managed care plans, a move that saved the state more than $30 million.[16]

~

Notes

[1] “Mapping pharmacy Deserts and Determining Accessibility to Community Pharmacy Services for Elderly Enrolled in a State Pharmaceutical Assistance Program,” Priti Pednekar and Andrew Peterson, PLoS ONE, June 2018; “Independently Owned Pharmacy Closures in Rural America, 2003-2018,” Abiodun Salako, Fred Ullrich, and Keith J. Mueller, Rural Policy Brief, July 2018; “’Pharmacy Deserts’ are Prevalent in Chicago’s Predominantly Minority Communities, Raising Medication Access Concerns,” PubMed, Qato, DM, Daviglus, ML, Wilder, J, Lee T, Qato, D, and Lambert B, November 2014. “Evaluation of Racial and Socioeconomic Disparities in Medication Pricing and Pharmacy Access and Services,” Marie A. Chisholm-Burns, Christina A. Spivey, Justin Gatwood, Adam Wiss, Kenneth Hohmeier, Steven R. Erickson, American Journal of Health System-Pharmacy, May 2018; “The State of Health Disparities in the United States,” Alina Baciu, Yamrot Negussie, Amy Geller, and James N. Weinstein, Communities in Action, January 2011.

[2] ILSR Analysis of: “NCPA 2018 Digest,” Leon Michos, PhD, Erin Holmes, PharmD, PhD, National Community Pharmacists Association, November 2018.; The 2017 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers, Adam J. Fein, PhD, Drug Channels Institute, February 2017.

[3] See footnote 20.

[4] “The Top 15 U.S. Pharmacies of 2018: M&A Reshapes the Market,” Adam J. Fein, Drug Channels, February 2019.

[5] “Specialty Pharmacies Say Benefit Managers Are Squeezing Them Out,” Katie Thomas, New York Times, January 2017.

[6] For one example, see this Federal Trade Commission letter: shorturl.at/CDU58; “FTC Issues Report on PBM Ownership of Mail-Order Pharmacies,” Federal Trade Commission, September 2005; “Improving Health Care: A Dose of Competition,” Federal Trade Commission and Department of Justice, July 2004; “PCMA Releases New Video: “What is Drug Price Transparency?”,” PCMA, February 2018.

[7] “Reports Show Pharmacy Middlemen Making Big Money in Other States,” Marty Schladen, The Columbus Dispatch, March 2019; “Pharmacy Middlemen Overcharged Medicaid $123.5 Million, State Says,” Lisa Gillespie, WFPL, February 2019; “Attorney General Dave Yost Seeks Reforms to Reign in PBM Abuses,” Darrel Rowland and Marty Schladen, The Columbus Dispatch, April 2019; “Federal and State Litigation Regarding Pharmacy Benefit Managers,” David A. Balto, January 2011.

[8] “Shop Around for Lower Drug Prices,” Lisa L. Gill, Consumer Reports, April 2018. “Finding the Right Pharmacy,” Consumer Reports, January 2014; “NCPA 2018 Digest,” Leon Michos, PhD, Erin Holmes, PharmD, PhD, National Community Pharmacists Association, November 2018; “Medication Use Drops When Local Drugstores Close.” Carolyn Crist, Reuters, May 2019; “Consumers Still Prefer Independent Pharmacies, CR’s Ratings Show,” Lisa L. Gill, Consumer Reports, December 2018.

[9] “Pharmacy Ownership Law – North Dakota,” Stacy Mitchell, Institute for Local Self-Reliance.

[10] To find out more about the state’s forward-thinking approach, and how well it serves residents, read our 2014 report and other reporting on the law here: https://ilsr.org/rule/pharmacy-ownership-laws/2832-2/.

[11] “Kentucky Senate Bill 107,” March 2013: https://legiscan.com/KY/bill/SB107/2013.

[12] “Analysis of State-Level Drug Pricing Transparency Laws in the United States,” Martha S. Ryan and Neeraj Sood, Jama Network, September 2019.

[13] Ibid.

[14] “Connecticut Legislation Supports Drug Pricing Transparency,” Jennifer Nessel, Pharmacy Times, July 2019.

[15] “Any Willing or Authorized Providers,” National Conference of State Legislators, November 2014.

[16] “Reining in Pharmacy Middlemen,” Zach Freed, Institute for Local Self-Reliance.